Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Styczynski, J; Tridello, G; Gil, L; Ljungman, P; Hoek, J; Iacobelli, S; Ward, KN; Cordonnier, C; Einsele, H; Socie, G; Milpied, N; Veelken, H; Chevallier, P; Yakoub-Agha, I; Maertens, J; Blaise, D; Cornelissen, J; Michallet, M; Daguindau, E; Petersen, E; Passweg, J; Greinix, H; Duarte, RF; Kröger, N; Dreger, P; Mohty, M; Nagler, A; Cesaro, S.
Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
J Clin Oncol. 2016; 34(19):2212-2220
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Greinix Hildegard
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
We investigated the effect of Epstein-Barr virus (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo-HSCT). The study included 11,364 patients who underwent allogeneic peripheral-blood or bone marrow transplantation for acute leukemia between 1997 and 2012. We analyzed the impact of donor and recipient EBV serologic status on overall survival, relapse-free survival, relapse incidence, nonrelapse mortality, and incidence of graft-versus-host disease (GVHD) after allo-HSCT. Patients receiving grafts from EBV-seropositive donors had the same overall survival as patients who received grafts from EBV-seronegative donors (hazard ratio [HR], 1.05; 95% CI, 0.97 to 1.12; P = .23). Seropositive donors also had no influence on relapse-free survival (HR, 1.04; 95% CI, 0.97 to 1.11; P = 0.31), relapse incidence (HR, 1.03; 95% CI, 0.94 to 1.12; P = .58), and nonrelapse mortality (HR, 1.05; 95% CI, 0.94 to 1.17; P = .37). However, in univariate analysis, recipients receiving grafts from seropositive donors had a higher risk of chronic GVHD than those with seronegative donors (40.8% v 31.0%, respectively; P < .001; HR, 1.42; 95% CI, 1.30 to 1.56). When adjusting for confounders, higher risk was identified for both acute and chronic GVHD. In seronegative patients with seropositive donors, the HR for chronic GVHD was 1.30 (95% CI, 1.06 to 1.59; P = .039). In seropositive patients with seropositive donors, the HR was 1.24 (95% CI, 1.07 to 1.45; P = .016) for acute GVHD and 1.43 (95% CI, 1.23 to 1.67; P < .001) for chronic GVHD. Seropositive patients with seronegative donors did not have an increased risk of GVHD. Our data suggest that donor EBV status significantly influences development of acute and chronic GVHD after allo-HSCT. © 2016 by American Society of Clinical Oncology.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Adult -
Aged -
Antibodies, Viral - blood
Child -
Child, Preschool -
Female -
Graft vs Host Disease - epidemiology
Hematopoietic Stem Cell Transplantation - adverse effects
Herpesvirus 4, Human - isolation & purification
Humans -
Incidence -
Infant -
Leukemia, Myeloid, Acute - therapy
Leukemia, Myeloid, Acute - virology
Male -
Middle Aged -
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - virology
Tissue Donors -

© Meduni Graz Impressum